1.Effect of Saponins Ⅰ Extracted from Paris Polyphylla on Coronary Artery Endothelial Cell Proliferation
Weiwei WANG ; Xuesong WU ; Hongmiao ZHANG ; Wen ZHANG ; Ying ZHANG ; Hong YE ; Tianhao BAO
Journal of Kunming Medical University 2016;37(11):37-40
Objective To explore the effect of ParidissaponinⅠ (PSⅠ) on the proliferation of coronary artery endothelial cells (CAECs).Methods CAECs were cultured with PSⅠ.CAEC growth rate was calculated by using blood cell counting plate.Cell viability was measured by MTT.The expressions of cadherin and caspase3 mRNA were detected by RT-PCR.Results PSⅠ slowed down growth rate of CAECs,reduced cell viability of CAECs,decreased the expression of cadherin mRNA and increased the expression of caspase3 mRNA in CAECs.Conclusion PSⅠ inhibits the proliferation of CAECs and induces CAECs apoptosis.
2.Closed-loop management strategies for patients with severe mental disorder complicated with COVID-19 infection
Sichuan Mental Health 2022;35(6):489-492
With the fluctuating condition of the COVID-19 epidemic, the current findings remain unclear about the preventive measures and coping strategies for patients with severe mental disorders at the nodes of the transmission chain. Past experience in prevention and control has shown that establishing an effective system for emerging infectious disease prevention and control and establishing transitional wards in specialist mental healthcare institutions play a significant role in reducing the risk of epidemic transmission. However, there is no formulated strategy for the management of patients with severe mental disorders and COVID-19 infection who have recurrent or worsened mental symptoms during the diagnosis and treatment of COVID-19 and are unable to cooperate with the treatment in Fangcang shelter hospitals or infectious wards. Based on the field research in the front line of the epidemic prevention, this paper discusses the management strategies of patients with severe mental disorders and COVID-19 infection in the context of the practical difficulties in managing patients with severe mental disorders and COVID-19 infection, emergency management strategies, protective conditions for front-line psychiatric medical staff and the legal basis for the management of patients with severe mental disorders and COVID-19 infection in emergency situations.
3.Protective effects of Taraxasterol on oxidatively injured cardiomyocytes
Weiwei WANG ; Hongmiao ZHANG ; Lin WANG ; Tianhao BAO
Chongqing Medicine 2018;47(12):1572-1574,1579
Objective To observe the protective effect and mechanism of taraxasterol on cardiomyocytes in oxidative injury model caused by ischemia-reperfusion (I/R).Methods Mouse cardiomyocytes (CSC cells) were used as the study objects and divided into the normal control group,I/R group,taraxasterol treating I/R group (5,10,30 μmol/L) and positive control group.The cell viability was measured by MTT.The expressions of Caspase-3 and Bcl-2 were detected by RT-PCR.The expressions of superoxide dismutase (SOD) and malondialdehyde (MAD) were detected by biochemical methods.The expression of ERK1/2 was detected by western blot.Results MTT assay showed that 30 μmol/L taraxasterol increased the cell viability of CSC cells injured by I/R (P<0.05).The RT-PCR results showed that the expression of Caspase-3 mRNA was decreased with 10,30 μmol/L taraxasterol treatment,the difference was statistically significant when compared with I/R group (P<0.05).The expression of Bcl-2 mRNA was increased with 30 μmol/L taraxasterol treatment,the difference was statistically significant when compared with the I/R group (P<0.05).The biochemical method detection showed that 30 μmol/L taraxasterol induced SOD expression was increased and MAD expression was decreased,the difference was statistically significant when compared with the I/R group (P<0.05).Western blot detection showed that 30 μmol/L taraxasterol treatment increased the ratio of p-ERK1/2 to t-ERK1/2 in injured CSC cells (P<0.05).Conclusion Taraxasterol might inhibit ischemia-reperfusion caused cardiomyocyte oxidative injury by up-regulation of ERK1/2 expression.
4.Clinical Application Advances of Antipsychotic Drugs in Female Schizophrenic Patients
Haoran XING ; Xi ZHANG ; Wenjing DING ; Yingying ZHANG ; Tianhao BAO
Herald of Medicine 2023;42(12):1808-1812
Female patients with schizophrenia exhibit a slower rate of absorption and excretion,leading to higher blood levels of antipsychotic drugs in their bodies and consequently causing more drug side effects.Women also have different levels of estrogen at different stages of life,and estrogen improves the efficacy of antipsychotic drugs by increasing dopamine D2receptor sensitivity.It is necessary to adjust the dosage of antipsychotic medication based on the level of estrogen,while also monitoring indicators such as blood glucose,triglycerides,cholesterol,and prolactin to minimize medication side effects.Nevertheless,the current literatures do not provide specific treatment plans for schizophrenia tailored to different genders,which is not the optimal treatment strategy for female patients.This review aims to summarize and categorize the differences in prescription,pharmacokinetics,pharmacodynamics,efficacy,and side effects in female patients with schizophrenia,and to provide scientific recommendations for drug treatment strategies in different stages of a woman's life(premenopausal,pregnancy,lactation,postmenopausal).
5.Treatment progress of weight gain and abnormal lipid metabolism in patients with schizophrenia caused by clozapine and olanzapine
Li KANG ; Haixia WANG ; Guiming LIU ; Tianhao BAO
Sichuan Mental Health 2021;34(2):182-186
To address the issue of weight gain and abnormal lipid metabolism caused by clozapine and olanzapine administration in patients with schizophrenia, a qualitative and systematic review was carried out, thus providing references for clinical treatment and future research. This review embraces the aspects of pharmacotherapy, traditional Chinese medicine treatment and so on.
6.Efficacy of virtual reality technology in patients with schizophrenia treatment
Qing YUAN ; Dan LIU ; Xiaoqing FU ; Tianhao BAO
Sichuan Mental Health 2024;37(3):277-281
Schizophrenia is a severe mental illness primarily managed with medication. In recent years, with the rapid development of virtual reality (VR) technology, its application effect in mental illness has been widely concerned. This review aims to explore the application of VR technology in schizophrenia treatment and to provide references for clinical practice. By reviewing randomized controlled trials from both domestic and international sources, the therapeutic efficacy of VR technology in treating schizophrenia was evaluated. The findings consistently demonstrated that VR technology has a positive effect on hallucinations, cognitive function, stress management and emotional control, and social function recovery in schizophrenia. [Funded by National Natural Science Foundation of China (number, 82160269); "Spring City Plan" High level Talent Training Program Spring City Top Talents Special Project (number, C201914016)]